Conference Co-Chairs: Stefan Przyborski, Professor of Cell Technology, Durham University and Philip Hewitt, Global Head of Early Investigative Toxicology, Merck
3D Cell Culture is gaining momentum in the pharmaceutical industry on account of the advantages such models pose for in drug discovery, from improved clinical translation and predictivity, to patient safety and />
SMi’s 3D Cell Culture Conference will explore advances in the application of 3D cell models, from their employment in drug screening to reduce candidate attrition, to the latest insights into microphysiological systems, the regulatory landscape, and the clinical applications of 3D bioprinting
Event Hashtag: #SMi3DCellCulture
Key Benefits of Attending:
2 Interactive Workshops on 8th October 2022
Workshop A: Reducing attrition in drug discovery through the use of human translational cellular models
Workshop Leader: Wendy Rowan, Scientific Director, Novel Human Genetics, GSK
Workshop B: Bioprinting for 3D Cell Culture
Workshop Leader: Kenny Dalgarno, Professor of Manufacturing Engineering, Newcastle University
WHO SHOULD ATTEND?
Biotech / Pharma Companies - Team Leader, Junior Principle investigator, Cell and Molecular Scientist, Chief Scientific Officer, Deputy Director, Manager, Founder, CEO, Head, Director, Programme Manager, Lab Head, Toxicologist
Academia Professor - Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering
Solution Providers – Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director, Vice President, COO
Organisations / Regulatory – Director, Senior Science Advisor, Scientific Officer
9 Feb 2022 @ 09:00 am
10 Feb 2022 @ 05:00 pm
Duration: 1 days, 8 hours
United Kingdom
English en